Pegfilgrastim Clinical Trials

15 actively recruiting trials across 10 locations

Also known as: Dulastin, Filgrastim SD-01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, NeulastaTM, Neulastim, Neupogen, Neupopeg, Nyvepria, PEG-G-CSF, PEG-filgrastim, PEG-rhG-CSF, PF-06881894, Pegcyte, Pegfilgastim, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Udenyca®, Ziextenzo, filgrastim-SD/01, pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv

Filter by location:

Houston, Texas3 trials

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

M D Anderson Cancer Center

Phase 2

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

M D Anderson Cancer Center

Phase 2

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

M D Anderson Cancer Center

Phase 1/2

Other2 trials

Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

Phase 3

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

Phase 3

Seattle, Washington2 trials

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Birmingham, Alabama1 trial

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Children's Hospital of Alabama

Phase 2

Fairbanks, Alaska1 trial

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Fairbanks Memorial Hospital

Phase 2

Kingman, Arizona1 trial

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Kingman Regional Medical Center

Phase 2/3

Orange, California1 trial

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

Chao Family Comprehensive Cancer Center University of California, Irvine

Phase 1/2

Palo Alto, California1 trial

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Lucille Packard Children's Hospital Stanford

Phase 2

Boston, Massachusetts1 trial

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Boston Children's Hospital

Phase 1/2

Charlotte, North Carolina1 trial

Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

Levine Cancer Institute

Memphis, Tennessee1 trial

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

St. Jude Children's Research Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.